The board of directors of DaVita (DVA) increased the authorization under the company’s existing share repurchase program by $2B in additional repurchasing authority, the company disclosed in a regulatory filing. The amount of shares of common stock authorized to be repurchased under the new authorization does not include the amount remaining under the company’s existing share repurchase program authorized on September 5, 2024, it noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVA:
- Berkshire trimmed Apple, DaVita, Charter, Bank of America stakes in Q2
- Berkshire Hathaway takes new stake in UnitedHealth, trims Apple stake
- DaVita price target lowered to $148 from $164 at Truist
- DaVita price target lowered to $154 from $157 at TD Cowen
- DaVita price target lowered to $160 from $169 at Barclays